Division of Medical Sciences, Island Medical Program, University of Victoria, British Columbia, Canada.
CNS Neurosci Ther. 2012 Jan;18(1):77-86. doi: 10.1111/j.1755-5949.2011.00246.x.
Huntington’s disease (HD) is a hereditary neurodegenerative disorder caused by an unstable expansion of cytosine-adenine-guanine (CAG) repeats in the HD gene. The symptoms include cognitive dysfunction and severe motor impairment with loss of voluntary movement coordination that is later replaced by bradykinesia and rigidity. The neuropathology is characterized by neuronal loss mainly in the striatum and cortex, and the appearance of neuronal intranuclear inclusions of mutant huntingtin. The mechanisms responsible for neurodegeneration are still not fully understood although excitotoxicity and a consequent increase in intracellular calcium concentration as well as the activation of caspases and calapins are known to play a key role. There is currently no satisfactory treatment or cure for this disease. The YAC128 transgenic mice express the full-length human HD gene with 128 CAG repeats and constitute a unique model for the study of HD as they replicate the slow and biphasic progression of behavioral deficits characteristic of the human condition and show striatal neuronal loss. As such, these transgenic mice have been an invaluable model not only for the elucidation of the neurodegenerative pathways in HD, but also for the screening and development of new therapeutic approaches. Here, I will review the unique characteristics of this transgenic HD model and will provide a summary of the therapies that have been tested in these mice, namely: potentiation of the protective roles of wild-type huntingtin and mutant huntingtin aggregation, transglutaminase inhibition, inhibition of glutamate- and dopamine-induced toxicity, apoptosis inhibition, use of essential fatty acids, and the novel approach of intrabody gene therapy. The insights obtained from these and future studies will help identify potential candidates for clinical trials and will ultimately contribute to the discovery of a successful treatment for this devastating neurodegenerative disorder.
亨廷顿病(HD)是一种遗传性神经退行性疾病,由 HD 基因中胞嘧啶-腺嘌呤-鸟嘌呤(CAG)重复不稳定扩增引起。其症状包括认知功能障碍和严重的运动损伤,导致自愿运动协调丧失,随后出现运动迟缓(bradykinesia)和僵硬。神经病理学的特征是神经元丧失,主要发生在纹状体和皮层,以及突变亨廷顿蛋白的神经元核内包涵体的出现。尽管兴奋性毒性和随之而来的细胞内钙浓度增加以及半胱天冬酶和钙调蛋白的激活被认为起关键作用,但导致神经退行性变的机制仍未完全阐明。目前,对于这种疾病尚无满意的治疗或治愈方法。YAC128 转基因小鼠表达全长人类 HD 基因,具有 128 个 CAG 重复,是研究 HD 的独特模型,因为它们复制了人类疾病特征的缓慢和双相进展的行为缺陷,并显示纹状体神经元丧失。因此,这些转基因小鼠不仅是阐明 HD 神经退行性途径的宝贵模型,也是筛选和开发新治疗方法的模型。在这里,我将回顾该转基因 HD 模型的独特特征,并对这些小鼠中经过测试的治疗方法进行总结,即:增强野生型亨廷顿蛋白和突变型亨廷顿蛋白聚集的保护作用、转谷氨酰胺酶抑制、抑制谷氨酸和多巴胺诱导的毒性、抑制细胞凋亡、使用必需脂肪酸,以及内体基因治疗的新方法。从这些和未来的研究中获得的见解将有助于确定临床试验的潜在候选者,并最终有助于发现这种毁灭性神经退行性疾病的成功治疗方法。